Generic Pharmaceutical Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The generic pharmaceutical manufacturing industry in the European Union involves the commercial production of off-patent chemical drug therapies and biosimilars designed to offer cost-effective alternatives to originator medicines. Supported by national healthcare cost-containment strategies, generic medicines are a cornerstone of EU healthcare, accounting for approximately 56% of all dispensed prescription drugs across the region while representing only 22% of total pharmaceutical expenditure. The sector is experiencing a post-pandemic push toward reshoring critical active pharmaceutical ingredient (API) manufacturing, coupled with strategic shifts toward biosimilars and complex value-added

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Generic Pharmaceutical Manufacturing in European Union industry cover?

This industry comprises the manufacturing of generic small-molecule therapeutics, biosimilars, and value-added medicines that have lost patent exclusivity. It includes the synthesis of active pharmaceutical ingredients (APIs) and the formulation of finished dosage forms like tablets, capsules, injectables, and inhalers. Unlike the originator sector, these manufacturers focus on bioequivalence, process efficiency, and high-volume production.

• •Classified officially under NACE Code C21.2 (Manufacture of pharmaceutical preparations) and C21.1 (Manufacture of basic pharmaceutical products).
• •Encompasses both 'simple generics' (standard tablets/capsules) and complex 'specialty generics' or biosimilars.
• •Excludes initial novel drug discovery and preclinical development, focusing instead on bioequivalence testing and formulation engineering.

Who operates in the industry and how is it structured?

The European generic manufacturing market is characterized by a mix of massive multinational conglomerates and regional mid-sized operators. Production facilities are distributed throughout the EU, with prominent manufacturing hubs in Germany, France, Italy, Spain, and Poland. Manufacturers supply retail pharmacies, hospital networks, and national healthcare systems via extensive distribution networks.

• •Generic medicines supply approximately 56% of all dispensed medicines in Europe.
• •The market exhibits distinct national variations, with volume-based generic penetration exceeding 70% in Germany, compared to under 30% in countries like Greece.
• •According to Medicines for Europe, generic and biosimilar companies provide over 160,000 direct jobs across the continent.

What drives demand in the industry?

The primary demand driver is the pressing need for European public health systems to contain healthcare costs amid aging demographic profiles. Patent expiries of high-value biologic drugs are also expanding the market for biosimilars, which require highly technical manufacturing capabilities. Additionally, post-pandemic regulatory incentives to mitigate supply chain vulnerabilities are driving demand for local, European-based production.

• •Saves European national healthcare systems and patients over €100 billion annually compared to brand-name alternatives.
• •The European Union's aging population accelerates chronic disease prevalence, leading to increased volume demand for maintenance therapies.
• •Systematic national policies, such as mandatory generic substitution by pharmacists and International Nonproprietary Name (INN) prescribing, directly stimulate volume growth.

Who are the notable companies in the industry?

Competition in the EU generic pharmaceutical manufacturing sector is intense and primarily driven by price bidding in public tenders. To maintain profitability, large operators leverage economies of scale, vertical integration of API sourcing, and expansion into high-margin biosimilar portfolios. Market leaders maintain highly advanced, GMP-compliant manufacturing facilities across multiple EU member states.

• •Teva Pharmaceutical Industries Ltd operates extensive European manufacturing sites, serving as a primary supplier of generic medicines across the EU.
• •Viatris Inc, formed via the merger of Mylan and Upjohn, maintains a significant European manufacturing footprint and commercial operations.
• •Sandoz Group AG (formerly a division of Novartis AG) is a global leader in generics and biosimilars with major production hubs in Austria and Germany.
• •Sanofi SA, through its established medicines divisions and API manufacturing spin-off Euroapi, remains a key European player.

What are the recent trends and outlook?

The industry is witnessing an accelerating trend toward 'reshoring' or 'nearshoring' chemical synthesis and API production to reduce dependence on Asian supply chains. Rising operational costs, specifically energy, labor, and environmental compliance in the EU, are clashing with rigid price-cap policies, prompting calls for pricing reform. Technological focus is rapidly shifting toward biosimilars and complex drug-delivery systems.

• •In 2025, EU exports of medicinal and pharmaceutical products rose to €221 billion, reinforcing the region's position as a global pharmaceutical manufacturing powerhouse.
• •Rising environmental standards under the EU Green Deal are compelling manufacturers to invest in carbon-neutral production and green chemistry.
• •National tender policies are gradually shifting from 'solely lowest price' criteria to multi-winner criteria that reward supply security and European production.

How is the industry regulated?

Manufacturing generic pharmaceuticals in the EU is subject to stringent quality, safety, and environmental standards. Facilities must rigorously adhere to European Good Manufacturing Practice (GMP) standards, which are regularly audited by national competent authorities. Marketing authorizations are harmonized and managed through centralized, decentralized, or mutual recognition procedures.

• •The European Medicines Agency (EMA) oversees the scientific evaluation and safety monitoring of centrally authorized generic and biosimilar products.
• •Marketing Authorization Applications (MAAs) for generic products are filed under Article 10(1) of Directive 2001/83/EC, demonstrating bioequivalence to a reference product.
• •Manufacturers are strictly governed by the EU Falsified Medicines Directive (Directive 2011/62/EU), requiring serialization and tamper-evident packaging features on prescription packs.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat International Trade in Medicinal and Pharmaceutical Products Statistics Explained 2025 ·
• Medicines for Europe / European Generic and Biosimilar Medicines Association (EGA) Reports 2024 ·
• European Commission Directorate-General for Competition Pharmaceutical Sector Inquiry ·
• European Medicines Agency (EMA) Regulatory Framework for Generics and Biosimilars